Re: Depression as a Risk Factor for Cancer: Renewing a Debate on the Psychobiology of Disease

Croyle, stress and depression have been associated with the causation and acceleration of cardiovascular disease. Cardiovascular disease tends to cause death at a younger age than does cancer. Therefore, one would have a common risk factor (for cardiovascular disease and cancer) and a competing cause of death (from cardiovascular disease and cancer), which would confound any epidemiologic study where death from cancer is in part or in whole an end point.

I think the main value of studies in younger patients would be to determine whether stress and depression can have an effect on the recurrence or progression of cancer. The fact that such an association is being found more frequently (3) would lend further credence to the study by Penninx et al.

DAVID S. DAVID

REFERENCES


NOTE

Correspondence to: David S. David, M.D., F.A.C.P., Clinical Professor of Medicine, U.C.L.A. School of Medicine, 2222 Santa Monica Blvd., Suite 302, Santa Monica, CA 90404.

RESPONSE

A replication of our findings—that chronically depressed mood increases risk of cancer—in younger populations will give further credence to this link. However, if we are unable to find an association between chronically depressed mood and cancer in younger populations, this could indicate that age is indeed a modifier of the association between chronically depressed mood and cancer. The effect of many risk factors is attenuated with increasing age. Therefore, finding that the association between chronic depression and cancer is stronger at older age would provide provocative evidence that a synergistic effect exists between chronic depression and changes in aging that are known to increase vulnerability to cancer.

In our study, we did not have data available about the stage of cancer when diagnosed and the progression speed of the cancer. Consequently, other studies in both young and old populations should provide further information about the association between chronic depression and recurrence or progression of cancer. If these studies are positive, they would add further support to our findings, but studies of stage and progression of cancer may not necessarily reflect the same risk factors as those for incidence. All of these studies are needed to learn about possible pathways in the link between chronic depression and cancer. We would like to emphasize that further studies should focus on people with chronic depression because the most important implication of our study is that long-term depression increases risk for cancer.

BRENDA W. J. H. PENNINX

JACK M. GURALNIK

NOTES

Affiliations of authors: B. W. J. H. Penninx, Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam, The Netherlands; J. M. Guralnik, Epidemiology, Demography and Biometry Program, National Institute on Aging, Bethesda, MD.

Correspondence to: Brenda W. J. H. Penninx, Ph.D., Institute for Research in Extramural Medicine, Vrije Universiteit, v.d. Boechorststraat 7, 1081 BT Amsterdam, The Netherlands.

EDITOR’S NOTE

Robert T. Croyle declined to respond to David S. David’s correspondence.
tumor effects of Linomide. In an editorial accompanying the article by Joseph and Isaacs, Wahl and Kleiman (2) suggested, on the other hand, that tumor therapy protocols that combine Linomide with the antiangiogenic cytokine interleukin 12 (IL-12)—which induces interferon-gamma release and activates interleukin 12 (IL-12) which induces tumor necrosis factor-alpha in mice. Cancer Immunol Immunother 1997;45:100–8.

To confirm that IL-12 and Linomide, used alone or in combination, exert the antiangiogenic effects that were expected on the basis of previous reports, we used a tumor-induced angiogenesis model. This model was proven effective in a previous study of IL-12 and tumor necrosis factor (5). Short-term (3 consecutive days) intraperitoneal administration of either 0.1 μg IL-12 or 400 mg Linomide resulted in significant inhibition of blood vessel formation at the site of B16F10 murine melanoma cell injection (16.4 blood vessels per microscope field [95% confidence interval CI] = 14.7–18.1 vessels) and 16.0 blood vessels per field [95% CI = 15.2–16.8 vessels] in IL-12 and Linomide-treated mice, respectively) as compared with diluent-injected controls (18.7 vessels per field [95% CI = 17.8–19.5 blood vessels]; two-sided \(P = .007\) for IL-12 versus control group; two-sided \(P = .0003\) for Linomide versus control group; Mann–Whitney U test). Combined treatment with IL-12 and Linomide was statistically significantly more effective in inhibiting the formation of new blood vessels than was the treatment with either agent alone (13.7 blood vessels per field [95% CI = 12.3–15.1 vessels]; two-sided \(P = .012\) for IL-12 versus combined treatment group; two-sided \(P = .0028\) for Linomide versus combined treatment group).

Our results demonstrate potentiation of antitumor and antiangiogenic effects for combination therapy with IL-12 and Linomide in a murine melanoma model. These observations would appear to be clinically interesting because antitumor efficacy of both these agents is currently being evaluated in clinical trials (6,7).

**Fig. 1.** Effects of treatment with interleukin 12 (IL-12) and/or Linomide® on B16F10 melanoma growth (IL-12 was a gift from the Genetics Institute Inc., Boston, MA, and Linomide was a gift from Pharmacia and Upjohn, Lund, Sweden). B6D2F1 mice were inoculated with \(1 \times 10^6\) melanoma cells in the footpad of the right hind limb and treated intratumorally with 0.1 μg IL-12 for 7 consecutive days and/or intraperitoneally with 400 mg/kg of Linomide for 21 days starting on day 7 after inoculation of tumor cells. As a control, the following diluents were used: 0.1% bovine serum albumin–phosphate-buffered saline (PBS) administered intratumorally for 7 consecutive days and 0.01% Tween in PBS administered intraperitoneally for 21 consecutive days. Groups consisted of seven to eight mice. Doses of IL-12 and Linomide were established in previous experiments (data not shown). Tumor growth was monitored as described previously (4). Tumor volumes are expressed as means with 95% confidence intervals. \(* = \text{two-sided } P < .05\) as compared with all other groups (Mann–Whitney U test). \(\bigcirc = \text{control}; \bigstar = \text{IL-12}; \square = \text{Linomide}; \nabla = \text{IL-12 + Linomide}.

**REFERENCES**


**NOTES**

Supported in part by grant II D79 from the Medical University of Warsaw and by grant 4 P05A 071 13 from the State Committee for Scientific Research.

**Affiliations of authors:** A. Dabrowska, Department of Immunology, Institute of Biostucture, Medical University of Warsaw, and Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland; J. Golab, A. Giermasz, M. Jakobiasiak (Department of Immunology, Institute of Biostucture), M. Markczak (Department of Dermatology), Medical University of Warsaw.

**Correspondence to:** Marek Jakobiasiak, M.D., Ph.D., Department of Immunology, Institute of Biostucture, Medical University of Warsaw, ul. Chalubinskiego 5, 02–004 Warsaw, Poland (e-mail: mjakobis@ib.amwaw.edu.pl).